•
Mar 30
Pfizer Q1 2025 Earnings Report
Pfizer delivered solid results despite revenue declines compared to the prior year.
Key Takeaways
Pfizer posted a strong adjusted EPS and net income despite a revenue decrease driven by lower Paxlovid sales. Cost-saving initiatives and R&D productivity improvements bolstered performance.
First-quarter revenues totaled $13715000000, down 8% year-over-year.
Adjusted diluted EPS increased by 12% to $0.92.
Net income reached $2967000000, slightly down from $3115000000 last year.
Operational efficiency and cost-saving measures are trending toward the upper end of 2025 EPS guidance.
Pfizer
Pfizer
Pfizer Revenue by Segment
Forward Guidance
Pfizer reaffirmed its full-year 2025 financial guidance, expecting revenues between $61000000000 and $64000000000 and adjusted diluted EPS between $2.80 and $3.00.
Positive Outlook
- Operational efficiency improvements are delivering cost savings.
- Strong R&D pipeline progress with new regulatory approvals and expansions.
- On track for $4.5B cost savings by 2025 with further productivity gains expected.
- Capital deployment focused on R&D and dividend payments.
- Expanded use of digital enablement and AI across operations.
Challenges Ahead
- Revenue impacted by sharp decline in Paxlovid sales.
- Higher manufacturer discounts due to Inflation Reduction Act affecting net prices.
- Unfavorable foreign exchange headwinds reduced revenues by 2%.
- Lower revenues from Eliquis and Xeljanz.
- Potential uncertainty from tariffs and trade policy changes not included in current guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income